Chen XC, Jiao DC, Qiao JH, Wang CZ, et al. De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial. Lancet Oncol 2024 Nov 26:S1470-2045(24)00581.
PMID: 39612919